Michael Dalrymple

Started in biotech (PPL Therapeutics, human therapeutic proteins in sheep milk, Dolly). 23+ years at MRC Technology/ LifeArc commercialising early stage research from academia. Licensing and research collaboration deals signed across all major territories. Led creation of MRCT's Centre for Drug Discovery and Centre for Diagnostics Development, including BD/diligence functions to support deal flow. Led deal resulting in creation of Keytruda, latterly monetised for US$1.5B. Instrumental in the establishment of the LifeArc Seed Investment Fund.